ARTHEx Biotech to Participate in Upcoming Investor and Industry Events

Valencia, Spain, Oct. 9, 2025 /PRNewswire/ — ARTHEx Biotech S.L., a clinical-stage biotechnology company focused on developing targeted RNA medicines for rare genetic neuromuscular disorders, announced today its participation in the following investor and industry events:

• 5th Annual Needham Private Biotech and MedTech Company Virtual 1×1 Forum
  • October 14-15, 2025 (virtual)
  • Frédéric Legros, Executive Chairman and CEO, will participate in one-on-one meetings with investors during the conference
• Chardan/Sanofi: The Double Helix Den: A closed-door symposium enabling unfiltered conversations on genetic medicines
  • October 20, 2025, New York, NY
  • Mr. Legros will be participating in a panel discussion titled “Clinical stage development: Balancing safety and maximizing clinical benefit”
• Chardan’s 9^th Annual Genetics Medicines Conference
  • October 21, 2025, New York, NY
  • Mr. Legros will participate in one-on-one meetings with investors during the conference

About ARTHEx Biotech

ARTHEx Biotech is a clinical-stage company developing targeted RNA medicines designed to precisely modulate gene expression. Its proprietary platform pairs selective oligonucleotides with tissue-specific delivery to reach skeletal muscle, heart, and brain. Its lead program, ATX-01, is in clinical evaluation for myotonic dystrophy type 1 (DM1), a rare neuromuscular disorder, in the Phase I/IIa ArthemiR™ trial. Building on this foundation, ARTHEx is advancing a pipeline of therapies for additional areas of high unmet need across muscular, CNS, and cardiac diseases.

The Company headquarters are in Valencia, Spain. 

For more information on ArthemiR™, please visit https://www.arthemir.com or https://clintrials.gov. For more information, please visit www.arthexbiotech.com and engage with us on LinkedIn.

View original content to download multimedia:https://www.prnewswire.com/news-releases/arthex-biotech-to-participate-in-upcoming-investor-and-industry-events-302579236.html

SOURCE ARTHEx Biotech